The Week In... Pharma (22-26/10)
  • Posted on: 26/10/2018
  • Category: The Week In...

The Week In... Pharma (22-26/10)

Get up to date with this week’s top pharma news! We’ve put together a selection of the top news items across the pharma sector this week - including latest Brexit updates, pioneering cancer research, and million of investment into UK Medicines Discovery - so take a look!

Interested in Star’s innovative outsourcing and resourcing solutions?

Contact Head of Business Development, Ryan Wooller, at ryan.wooller@starmedical.co.uk, or get in touch on 07748 464 079.

On the hunt for a new role, or just curious?

Visit our candidate page, submit your CV to candidates@starmedical.co.uk, or give our offices a ring!


£215 million additional investment for UK innovation centres

The UK Government is investing £215 million in the Digital, Medicines Discovery, Future Cities and Transport Systems Catapult centres, announced as part of the modern Industrial Strategy. 

Patients 'may need to stockpile own drugs if no-deal Brexit looms'

Representatives of the pharma industry have told the Commons health committee that patients should consider stockpiling their medication if it looks likely that the UK will leave the EU with no deal. 

New $2 million programme aims at increasing diversity in cancer research

The National Cancer Institute in the United States is developing a joint cancer drug discovery and development, and research education programme, focused on developing treatments for cancers that have an increased risk of causing death among ethnic minorities. 

UK science could be 'crippled' by a hard Brexit

The Francis Crick Institute and 29 Nobel Prize winners warn a hard Brexit could ‘cripple’ UK science as a survey suggests half of the Institute’s staff are likely to leave Britain after Brexit. 

UK seizes more than £2 million of fake medicines

The Medicines and Healthcare products Regulatory Agency (MHRA), has seized more than one million doses-worth of fake medicines and medical devices worth in excess of £2 million.